The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer—Primary endpoint, pathological complete response (pCR).
Helena Margaret Earl
Honoraria - Roche
Research Funding - Roche/Genentech
Louise Hiller
No relevant relationships to disclose
Clare Blenkinsop
No relevant relationships to disclose
Louise Grybowicz
No relevant relationships to disclose
Anne-Laure Vallier
No relevant relationships to disclose
Jean Abraham
No relevant relationships to disclose
Jeremy Thomas
No relevant relationships to disclose
Elena Provenzano
No relevant relationships to disclose
Luke Hughes-Davies
No relevant relationships to disclose
Karen McAdam
Honoraria - Amgen
Steve Chan
Honoraria - advisory board
Rizvana Ahmad
No relevant relationships to disclose
Tamas Hickish
Honoraria - advisory board
Stephen Houston
Honoraria - Roche
Daniel Rea
No relevant relationships to disclose
John M. S. Bartlett
Research Funding - Roche
Carlos Caldas
No relevant relationships to disclose
David A. Cameron
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
Janet Dunn
No relevant relationships to disclose
Richard L Hayward
Research Funding - Roche